THOUSAND OAKS, Calif., Sept. 10, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the appointment of Ray Jordan to the new position of senior vice president, Corporate Affairs, effective October 1.
Jordan will report directly to Robert A. Bradway, president and chief executive officer, and will be responsible for strategic communications across Amgen, including internal and external communications, issues management and philanthropy.
Since 2003 Jordan has served as communications leader at Johnson & Johnson, responsible for corporate communications and public affairs for more than 250 operating companies in 60 countries. Prior to joining Johnson & Johnson, Jordan was vice president, communications and information, for Pfizer, where he held a range of positions over the course of 17 years. He also served as chair of PhRMA's public affairs section and of the National Pharmaceutical Council's User Group. Earlier in his career, Jordan was a reporter for a regional daily newspaper and held positions with Bristol-Myers and Dun & Bradstreet.
"We are very pleased to have Ray join Amgen," said Bradway. "He is a strategic thinker and communicator with skills honed at two respected global health care companies. Ray's background in both business management and communication will serve Amgen well as we execute on our strategy to deliver results for both patients and shareholders."
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
David Caouette, 805-447-2661 (media)
Arvind Sood, 805-447-1060 (investors)